f Chaperone-Hsp90 Conjugation Mediated Targeting Technology for Cancer Treatment: Pioneer Innovation in Nanomedicine

References

1. McCombsJ.R. ChangH.P. ShahD.K. OwenS.C. Antibody-drug conjugate and free geldanamycin combination therapy enhances anti-cancer efficacy.Int. J. Pharm.202161012127210.1016/j.ijpharm.2021.121272 34763035
   [Google Scholar]
2. HamamotoR. ToyokawaG. NakakidoM. UedaK. NakamuraY. SMYD2-dependent HSP90 methylation promotes cancer cell proliferation by regulating the chaperone complex formation.Cancer Lett.2014351112613310.1016/j.canlet.2014.05.014 24880080
   [Google Scholar]
3. SukumaranS. TanM. Ben-UlielS.F. Rational design, synthesis and structural characterization of peptides and peptidomimetics to target Hsp90/Cdc37 interaction for treating hepatocellular carcinoma.Comput. Struct. Biotechnol. J.2023213159317210.1016/j.csbj.2023.05.023 37304004
   [Google Scholar]
4. ZhangX. ChenY. YangB. Driving the degradation of oncofusion proteins for targeted cancer therapy.Drug Discov. Today202328610358410.1016/j.drudis.2023.103584
   [Google Scholar]
5. LuD. LiuR. ZhouY. FOXO3a-dependent up-regulation of HSP90 alleviates cisplatin-induced apoptosis by activating FUNDC1-mediated mitophagy in hypoxic osteosarcoma cells.Cell. Signal.202310111050010.1016/j.cellsig.2022.110500 36270475
   [Google Scholar]
6. GaoJ. ZhouC. ZhongY. Dipyridamole interacts with the N-terminal domain of HSP90 and antagonizes the function of the chaperone in multiple cancer cell lines.Biochem. Pharmacol.202320711537610.1016/j.bcp.2022.115376 36513142
   [Google Scholar]
7. SeoE.J. KhelifiD. FayezS. Molecular determinants of the response of cancer cells towards geldanamycin and its derivatives.Chem. Biol. Interact.202338311067710.1016/j.cbi.2023.110677
   [Google Scholar]
8. ChoiS.H. ChoS.Y. ParkS.Y. HurM.W. Post-translational regulation of proto-oncogene ZBTB7A expression by p53 status in cancer cells: HSP90-dependent stabilization vs. p53-KLHL20-ubiquitin proteasomal degradation.Biochim. Biophys. Acta. Gene Regul. Mech.20231866219493110.1016/j.bbagrm.2023.194931 37011832
   [Google Scholar]
9. VargaA. NguyenM.T. PénzesK. Protein kinase D3 (PKD3) requires Hsp90 for stability and promotion of prostate cancer cell migration.Cells202312221210.3390/cells12020212 36672148
   [Google Scholar]
10. NoureddineJ. MuB. HamidzadaH. Knockout of endoplasmic reticulum localized molecular chaperone HSP90.7 impairs seeding development and cellular auxin homeostasis in Arabidopsis.bioRxiv202310.1101/2023.03.06.531358
    [Google Scholar]
11. VotraS.D. AlsalihD. BourbouliaD. Methods to assess the impact of Hsp90 chaperone function on extracellular client MMP2 activity.In: Chaperones: Methods and Protocols.2213210.1007/978‑1‑0716‑3342‑7_17
    [Google Scholar]
12. ShenD. ZhaoQ. WangM. Developing an affinity-based chemical proteomics method to in situ capture amorphous aggregated proteome and profile its heterogeneity in stressed cells.Anal. Chem.202395156358636610.1021/acs.analchem.2c05689 37017602
    [Google Scholar]
13. NguyenV. AhlerE. SitkoK.A. Molecular determinants of Hsp90 dependence of Src kinase revealed by deep mutational scanning.Protein Sci.2023327e465610.1002/pro.4656
    [Google Scholar]
14. JafariA. Rezaei-TaviraniM. FarhadihosseinabadiB. TaranejooS. ZaliH. HSP90 and co-chaperones: Impact on tumor progression and prospects for molecular-targeted cancer therapy.Cancer Invest.202038531032810.1080/07357907.2020.1752227 32274949
    [Google Scholar]
15. BobrovE. SkobelevaN. RestifoD. Targeted delivery of chemotherapy using HSP90 inhibitor drug conjugates is highly active against pancreatic cancer models.Oncotarget2017834399440910.18632/oncotarget.12642 27779106
    [Google Scholar]
16. MarcionG. HermetetF. NeiersF. Nanofitins targeting heat shock protein 110: An innovative immunotherapeutic modality in cancer.Int. J. Cancer2021148123019303110.1002/ijc.33485 33506516
    [Google Scholar]